Richard M. Lush - Concepedia

Author

Richard M. Lush

National Cancer Institute

Also Known As

Deborah Lue, Lee, Ruey-min, R LUSH, R Lush, R M Lush, R. LUSH, R. Lush, R.M. Lush, RICHARD LUSH, Richard Lush

103

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Moffitt Cancer Center University of South Florida National Institutes of Health Johns Hopkins University

About

Richard M. Lush is an author at National Cancer Institute specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1.1K
2	Engineering	1	1	14
3	Health Sciences	1	1	22
4	Natural Sciences	1	1	15
5	Biochemistry	1	1	15

Richard M. Lush

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
<i>All-trans</i>-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients Noweeda Mirza, Mayer Fishman, Ingo Fricke, Cancer Research	2006	549
All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Sergei Kusmartsev, Fengdong Cheng, Bin Yu, PubMed Cell TherapyImmunologyImmunoeditingImmunotherapyTumor Biology	2003	461
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson, Journal of Clinical Oncology	1998	408
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms Edward A. Sausville, Susan G. Arbuck, Richard A. Messmann, Journal of Clinical Oncology	2001	294
Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study Pamela N. Münster, Douglas C. Marchion, Elona Biçaku, Journal of Clinical Oncology	2007	218
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. Lauri Welles, M. Wayne Saville, Jill Lietzau, Journal of Clinical Oncology	1998	174
A phase I study of indoximod in patients with advanced malignancies Hatem Soliman, Susan Minton, Hyo S. Han, Oncotarget	2016	141
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma Bert H. O’Neil, Laura W. Goff, John Kauh, Journal of Clinical Oncology Metastatic HccPathologyPhase Ii StudyOncologyHepatobiliary Tumor	2011	140
A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer Alain Thibault, William D. Figg, Raymond C. Bergan, Tumori Journal	1998	136
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial Adil Daud, Jana L. Dawson, Ronald C. DeConti, Clinical Cancer Research	2009	88

Page 1